Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 10, Issue 1, Pages 152
Publisher
MDPI AG
Online
2021-01-05
DOI
10.3390/jcm10010152
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation
- (2021) Athanasios D. Anastasilakis et al. CALCIFIED TISSUE INTERNATIONAL
- Combination and sequential treatment in women with postmenopausal osteoporosis
- (2020) Athanasios D. Anastasilakis et al. EXPERT OPINION ON PHARMACOTHERAPY
- A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
- (2020) Judith Everts‐Graber et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial
- (2020) Anne Sophie Sølling et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
- (2020) Katharina Jähn-Rickert et al. Frontiers in Endocrinology
- Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis
- (2020) Houchen Lyu et al. ANNALS OF INTERNAL MEDICINE
- Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment
- (2020) Hideomi Kondo et al. JOURNAL OF BONE AND MINERAL METABOLISM
- The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis
- (2020) Polyzois Makras et al. BONE
- RANKL as a therapeutic target of rheumatoid arthritis
- (2020) Sakae Tanaka et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
- (2020) Elena Tsourdi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study
- (2020) J. Everts-Graber et al. BONE
- Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough
- (2020) Athanasios D. Anastasilakis et al. JOURNAL OF CLINICAL DENSITOMETRY
- Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports
- (2019) O. Lamy et al. OSTEOPOROSIS INTERNATIONAL
- Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature
- (2019) Helena Florez et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Relationship Between Bone Mineral Density T‐score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
- (2019) S Ferrari et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Spontaneous Vertebral Fractures in Males with Osteoporosis After Denosumab Discontinuation
- (2019) Panagiotis Anagnostis et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women
- (2019) A. Fassio et al. BONE
- Repeating Measurement of Bone Mineral Density When Monitoring With Dual-Energy X-Ray Absorptiometry: The 2019 ISCD Official Positions
- (2019) David L. Kendler et al. JOURNAL OF CLINICAL DENSITOMETRY
- Standard vs Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial
- (2019) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial
- (2019) Athanasios D. Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors
- (2019) Elena Gonzalez-Rodriguez et al. BREAST CANCER RESEARCH AND TREATMENT
- Bone Mineral Density After Transitioning From Denosumab to Alendronate
- (2019) David Kendler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider
- (2019) Liana Tripto-Shkolnik et al. BONE
- Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
- (2018) Albrecht Werner Popp et al. CALCIFIED TISSUE INTERNATIONAL
- Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
- (2018) Anne M. Horne et al. CALCIFIED TISSUE INTERNATIONAL
- Certainties and Uncertainties About Denosumab Discontinuation
- (2018) Elena Tsourdi et al. CALCIFIED TISSUE INTERNATIONAL
- Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates
- (2018) Liana Tripto-Shkolnik et al. CALCIFIED TISSUE INTERNATIONAL
- THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
- (2018) Athanasios D Anastasilakis et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far We've Come, How Much Further We Need to Go
- (2018) Stavros C Manolagas JOURNAL OF BONE AND MINERAL RESEARCH
- Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman
- (2018) Sunita M. C. De Sousa et al. CLINICAL ENDOCRINOLOGY
- Vertebral fractures cascade: potential causes and risk factors
- (2018) H. Che et al. OSTEOPOROSIS INTERNATIONAL
- Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment
- (2017) Athanasios D Anastasilakis et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
- (2017) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
- (2017) Athanasios D Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis
- (2017) R. Niimi et al. OSTEOPOROSIS INTERNATIONAL
- Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates
- (2017) B. Uebelhart et al. OSTEOPOROSIS INTERNATIONAL
- Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
- (2017) T. Lehmann et al. OSTEOPOROSIS INTERNATIONAL
- Observations following discontinuation of long-term denosumab therapy
- (2017) M. R. McClung et al. OSTEOPOROSIS INTERNATIONAL
- Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
- (2017) M. B. Zanchetta et al. OSTEOPOROSIS INTERNATIONAL
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis
- (2016) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report
- (2016) Olivier Lamy et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cancel the denosumab holiday
- (2016) M. R. McClung OSTEOPOROSIS INTERNATIONAL
- Hypercalcemia after discontinuation of long-term denosumab treatment
- (2016) A. S. Koldkjær Sølling et al. OSTEOPOROSIS INTERNATIONAL
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- (2015) Benjamin Z Leder et al. LANCET
- Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
- (2015) B. Aubry-Rozier et al. OSTEOPOROSIS INTERNATIONAL
- Multiple clinical vertebral fractures following denosumab discontinuation
- (2015) A. D. Anastasilakis et al. OSTEOPOROSIS INTERNATIONAL
- Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics
- (2015) A. W. Popp et al. OSTEOPOROSIS INTERNATIONAL
- Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone
- (2015) Xiaolin Tu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone
- (2015) Jinhu Xiong et al. PLoS One
- Tartrate-resistant acid phosphatase (TRAP) co-localizes with receptor activator of NF-KB ligand (RANKL) and osteoprotegerin (OPG) in lysosomal-associated membrane protein 1 (LAMP1)-positive vesicles in rat osteoblasts and osteocytes
- (2014) L. B. Solberg et al. HISTOCHEMISTRY AND CELL BIOLOGY
- For whom the bell tolls: Distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases
- (2012) Stavros C. Manolagas et al. BONE
- Denosumab: mechanism of action and clinical outcomes
- (2012) D. A. Hanley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
- (2012) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility
- (2012) Maria-Luisa Brandi et al. Therapeutics and Clinical Risk Management
- Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study
- (2011) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Evidence for osteocyte regulation of bone homeostasis through RANKL expression
- (2011) Tomoki Nakashima et al. NATURE MEDICINE
- Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
- (2011) N. Freemantle et al. OSTEOPOROSIS INTERNATIONAL
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
- (2009) David L Kendler et al. JOURNAL OF BONE AND MINERAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now